| Literature DB >> 24865417 |
Letizzia Dall'Agnol1, Liciane Fernandes Medeiros2, Iraci L S Torres3, Alicia Deitos1, Aline Brietzke1, Gabriela Laste4, Andressa de Souza5, Júlia Lima Vieira6, Felipe Fregni7, Wolnei Caumo8.
Abstract
UNLABELLED: Chronic myofascial pain syndrome has been related to defective descending inhibitory systems. Twenty-four females aged 19 to 65 years with chronic myofascial pain syndrome were randomized to receive 10 sessions of repetitive transcranial magnetic stimulation (rTMS) (n = 12) at 10 Hz or a sham intervention (n = 12). We tested if pain (quantitative sensory testing), descending inhibitory systems (conditioned pain modulation [quantitative sensory testing + conditioned pain modulation]), cortical excitability (TMS parameters), and the brain-derived neurotrophic factor (BDNF) would be modified. There was a significant interaction (time vs group) regarding the main outcomes of the pain scores as indexed by the visual analog scale on pain (analysis of variance, P < .01). Post hoc analysis showed that compared with placebo-sham, the treatment reduced daily pain scores by -30.21% (95% confidence interval = -39.23 to -21.20) and analgesic use by -44.56 (-57.46 to -31.67). Compared to sham, rTMS enhanced the corticospinal inhibitory system (41.74% reduction in quantitative sensory testing + conditioned pain modulation, P < .05), reduced the intracortical facilitation in 23.94% (P = .03), increased the motor evoked potential in 52.02% (P = .02), and presented 12.38 ng/mL higher serum BDNF (95% confidence interval = 2.32-22.38). No adverse events were observed. rTMS analgesic effects in chronic myofascial pain syndrome were mediated by top-down regulation mechanisms, enhancing the corticospinal inhibitory system possibly via BDNF secretion modulation. PERSPECTIVE: High-frequency rTMS analgesic effects were mediated by top-down regulation mechanisms enhancing the corticospinal inhibitory, and this effect involved an increase in BDNF secretion.Entities:
Keywords: Myofascial pain syndrome; brain-derived neurotrophic factor; clinical trial; quantitative sensory testing; transcranial magnetic simulation
Mesh:
Substances:
Year: 2014 PMID: 24865417 DOI: 10.1016/j.jpain.2014.05.001
Source DB: PubMed Journal: J Pain ISSN: 1526-5900 Impact factor: 5.820